Gastroenterology

Gastroenterology

Volume 142, Issue 7, June 2012, Pages 1592-1609
Gastroenterology

AGA
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

https://doi.org/10.1053/j.gastro.2012.04.001Get rights and content

Abbreviations

NAFLD
Nonalcoholic Fatty Liver Disease
NAFL
Nonalcoholic Fatty Liver
NASH
Nonalcoholic Steatohepatitis
T2DM
Type 2 Diabetes Mellitus
AST
Aspartate Aminotransferase
ALT
Alanine Aminotransferase
HOMA
Homeostatic Model Assessment
RCT
Randomized Controlled Trial
PIVENS
Pioglitazone versus Vitamin E versus Placebo for the Treatment of Non-diabetic patients with Nonalcoholic steatohepatitis
TONIC
Treatment of Nonalcoholic Fatty Liver Disease in Children
NAS
NAFLD Activity Score
CK18
Cytokeratin 18 Fragments
ELF
Enhanced Liver Fibrosis Panel
TZD
Thiazolidinediones
UDCA
Ursodeoxycholic Acid
ANA
Anti Nuclear Antibody
ASMA
Anti Smooth Muscle Antibody
US
Ultrasound
CT
Computerized Tomography
MR
Magnetic Resonance

Cited by (0)

This article is being published jointly in 2012 in Gastroenterology, American Journal of Gastroenterology, and Hepatology.

Potential Conflicts of Interest Naga Chalasani, MD, FACG has received compensation for providing consulting related to NAFLD and NASH from Amylin, Gilead, Genentech, and Mochida and he has received research support from Amylin, Eli Lilly, Intercept, and Cumberland Pharmaceuticals in the last 3 years. Over the last 3 years, he has received compensation for providing consultation related to drug hepatotoxicity from J & J, Merck, GlaxoSmithKline, Karo Bio, Salix, Advanced Life Sciences, BMS, Teva Pharmaceuticals, Abbott, Biolex, Sanofi-Aventis, and Vertex.

Zobair Younossi, MD has received consulting fees from Salix, Tibotec, and Vertex.

Anna Mae Diehl, MD has received compensation for providing consulting related to NAFLD from Vertex, Norgine, and Celgene.

Elizabeth Brunt, MD has received compensation from Amylin, Pfizer, and Geneva Foundation for NASH consulting.

Kenneth Cusi, MD has received compensation from Merck, Daichi-Sankyo, and Roche for providing consulting.

Michael Charlton, MD has received compensation from Gilead and Genentech for providing consulting related to NAFLD and NASH.

Joel Lavine, MD, PhD has received compensation for providing consultations related to NAFLD from Quark Pharmaceuticals and Synageva BioPharma, and received research support from Raptor Pharmaceuticals, all in the last 3 years.

Arun Sanyal, MD has served as an ad hoc advisor to Roche, Takeda, Merck, Astella, Sanofi, Exhalenz, and Immuron. He serves as the global PI for trials for Exhalenz and Immuron.

View Abstract